Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: Is the effect dependent on the type of GnRH analogue used for pituitary suppression?

Reproductive BioMedicine Online

Volumn 20, Issue 1, 2010, Pages 165-166

  Ata, B ^a   Urman, B ^a  

^a AMERICAN HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; PLACEBO; TRIPTORELIN;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO TRANSFER; ESTRUS CYCLE; FEMALE; HORMONE INHIBITION; HUMAN; INFERTILITY THERAPY; LETTER; LUTEAL PHASE; MENSTRUAL CYCLE; NIDATION; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; PREGNANCY RATE; REPRODUCIBILITY; SINGLE DRUG DOSE;

EID: 77149142268     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.10.022     Document Type: Letter

References (4)

1. Ata, B., Yakin, K., Balaban, B., et al., 2008. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reprod. 23, 668-673.
2. Isik, A.Z., Caglar, G.S., Sozen, E., et al., 2009. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod. BioMed. Online 19, 472-477.
3. Kol, S., Dor, J., 2009. Symposium: update on prediction and management of OHSS. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation. Reprod. BioMed. Online 19, 59-60.
4. Tesarik, J., Hazout, A., Mendoza-Tesarik, R., et al., 2006. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Human Reprod. 21, 2572-2579.